Manuscript Publications

1. Willis M, Fridhammar A, Gundgaard J, Nilsson A, Johansen P. Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. Pharmacoeconomics. 2020 Sep;38(9):953-69.

2. Willis M, Asseburg C, Slee A, Nilsson A, Neslusan C. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data. Manuscript Development in Progress. 2020.

3. Si L, Willis MS, Asseburg C, Nilsson A, Tew M, Clarke PM, et al. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health. 2020.

4. Persson S, Johansen P, Andersson E, Lindgren P, Thielke D, Larsen Thorsted B, et al. Days absent from work due to complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. Diabetes, Obesity and Metabolism (DOM). 2020 April 24.

5. Willis M, Asseburg C, Nilsson A, Neslusan C. Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2019 Oct;10(5):1753-69.

6. Willis M, Asseburg C, Neslusan C. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes research and clinical practice. 2019 Feb;148:222-33.

7. Toresson Grip E, Svensson AM, Miftaraj M, Eliasson B, Franzen S, Gudbjornsdottir S, et al. Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register. Diabetes care. 2019 Apr;42(4):545-52.

8. Persson E, Persson S, Gerdtham U, Steen Carlsson K. Effect of type 1 diabetes on school performance in a dynamic world: new analysis exploring Swedish register data. Applied Economics. 2019 2019/05/21;51(24):2606-22.

9. Johansen P, Hakan-Bloch J, Liu AR, Bech PG, Persson S, Leiter LA. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics – open. 2019 Mar 29.

10. Gupta V, Willis M, Johansen P, Nilsson A, Shah M, Mane A, et al. Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in health regional issues. 2019 May;18:65-73.

11. Ericsson Å, Fridhammar A. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. Journal of medical economics. 2019 Oct;22(10):997-1005.

12. Willers C, Iderberg H, Axelsen M, Dahlstrom T, Julin B, Leksell J, et al. Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study. PloS one. 2018;13(6):e0199170.

13. Persson S, Dahlquist G, Gerdtham UG, Steen Carlsson K. Why childhood-onset type 1 diabetes impacts labour market outcomes: a mediation analysis. Diabetologia. 2018 Feb;61(2):342-53.

14. Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, et al. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jun;21(6):724-31.

15. Neslusan C, Teschemaker A, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2018 Apr;9(2):565-81.

16. Julin B, Willers C, Leksell J, Lindgren P, Loostrom Muth K, Svensson AM, et al. Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden. Diabetes Metabolism research and reviews. 2018 May;34(4):e2984.

17. Ericsson Å, Glah D, Lorenzi M, Jansen J, Fridhammar A. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PloS one. 2018;13(2):e0191953.

18. Andersson E, Welin K-O, Steen Carlsson K. Kostnader för fetma i Sverige idag och år 2030. IHE Rapport 2018:3. Lund: IHE; 2018.

19. Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Pharmacoeconomics. 2017 Mar;35(3):375-96.

20. Willis M, Asseburg C, Nilsson A, Johnsson K, Kartman B. Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017 Mar;20(3):357-71.

21. Lovén I, Steen Carlsson K. Early Onset of Type 1 Diabetes and Educational Field at Upper Secondary and University Level: Is Own Experience an Asset for a Health Care Career? International journal of environmental research and public health. 2017 Jun 30;14(7).

22. Ericsson A, Lundqvist A. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Applied health economics and health policy. 2017 Apr;15(2):237-48.

23. Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique. 2016;23(2):e151-68.

24. Persson S, Gerdtham UG, Steen Carlsson K. Labor market consequences of childhood onset type 1 diabetes. Economics and human biology. 2016 Dec;23:180-92.

25. Henriksson M, Jindal R, Sternhufvud C, Bergenheim K, Sorstadius E, Willis M. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. Pharmacoeconomics. 2016 Jun;34(6):569-85.

26. Steen Carlsson K, Hjalte F, Lundqvist A, Ragnarson T, Häger G, Nilsson S, et al. Nationella riktlinjer Diabetesvård 2015. Stöd för styrning och ledning. Stockholm2015.

27. Pickwell K, Siersma V, Kars M, Apelqvist J, Bakker K, Edmonds M, et al. Predictors of lower-extremity amputation in patients with an infected diabetic foot ulcer. Diabetes care. 2015 May;38(5):852-7.

28. Oien RF, Forssell H, Ragnarson Tennvall G. Cost consequences due to reduced ulcer healing times – analyses based on the Swedish Registry of Ulcer Treatment. International wound journal. 2015 Jun 30.

29. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-Effectiveness of Canagliflozin versus Sitagliptin as add-on to Metformin in patients with type 2 diabetes mellitus in Mexico. Value in health regional issues. 2015;8:8-19.

30. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in health regional issues. 2015 Dec;8:8-19.

31. Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. Journal of Medical Economics. 2014;17(9):658-69.

32. Siersma V, Thorsen H, Holstein PE, Kars M, Apelqvist J, Jude EB, et al. Health-related quality of life predicts major amputation and death, but not healing, in people with diabetes presenting with foot ulcers: the Eurodiale study. Diabetes care. 2014;37(3):694-700.

33. Lundqvist A, Steen Carlsson K, Johansen P, Andersson E, Willis M. Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations. PloS one. 2014;9(10):e110235.

34. Kiadaliri AA, Gerdtham UG, Eliasson B, Gudbjornsdottir S, Svensson AM, Carlsson KS. Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. International journal of environmental research and public health. 2014 May 7;11(5):4939-52.

35. Kiadaliri AA, Gerdtham UG, Eliasson B, Carlsson KS. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2014 Dec;5(2):591-607.

36. Borg S, Palaszewski B, Gerdtham UG, Fredrik O, Roos P, Gudbjornsdottir S. Patient-reported outcome measures and risk factors in a quality registry: a basis for more patient-centered diabetes care in Sweden. International journal of environmental research and public health. 2014 Nov 26;11(12):12223-46.

37. Borg S, Näslund I, Persson U, Ödegaard K. Obesity and Surgical Treatment – A Cost-Effectiveness Assessment for Sweden. Nordic Journal of Health Economics. 2014;2(1):257-75.

38. Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). Journal of medical economics. 2013 Aug;16(8):1007-21.

39. Saha S, Leijon M, Gerdtham U, Sundquist K, Sundquist J, Arvidsson D, et al. A culturally adapted lifestyle intervention addressing a Middle Eastern immigrant population at risk of diabetes, the MEDIM (impact of Migration and Ethnicity on Diabetes in Malmö): study protocol for a randomized controlled trial. Trials. 2013;14:279.

40. Pickwell KM, Siersma VD, Kars M, Holstein PE, Schaper NC. Diabetic foot disease: impact of ulcer location on ulcer healing. Diabetes Metabolism research and reviews. 2013 Jul;29(5):377-83.

41. Persson S, Dahlquist G, Gerdtham UG, Steen Carlsson K. Impact of childhood-onset type 1 diabetes on schooling: a population-based register study. Diabetologia. 2013 Jun;56(6):1254-62.

42. Kiadaliri A, Gerdtham U, Nilsson P, Eliasson B, Gudbjornsdottir S, Carlsson K. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PloS one. 2013;8(5):e62650.

43. Kiadaliri A, Clarke P, Gerdtham U, Nilsson P, Eliasson B, Gudbjornsdottir S, et al. Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register. Journal of diabetes research. 2013;2013:241347.

44. Tiberg I, Carlsson Steen K, Carlsson A, Hallstrom I. Children diagnosed with type 1 diabetes: a randomized controlled trial comparing hospital versus home-based care. Acta paediatrica (Oslo, Norway : 1992). 2012 Oct;101(10):1069-73.

45. Tiberg I, Carlsson KS, Carlsson A, Hallstrom I. Metabolic control, healthcare satisfaction and costs 1 month after diagnosis of type 1 diabetes: a randomised controlled trial of hospital-based care vs. hospital-based home care. Pediatric diabetes. 2012 Dec;13(8):625-31.

46. Borg S, Naslund I, Persson U, Odegaard K. Budget impact analysis of surgical treatment for obesity in Sweden. Scandinavian journal of surgery: SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society. 2012;101(3):190-7.

47. Anderberg E, Steen Carlsson K, Berntorp K. Use of healthcare resources after gestational diabetes mellitus: a longitudinal case-control analysis. Scandinavian journal of public health. 2012 Jun;40(4):385-90.

48. van Battum P, Schaper N, Prompers L, Apelqvist J, Jude E, Piaggesi A, et al. Differences in minor amputation rate in diabetic foot disease throughout Europe are in part explained by differences in disease severity at presentation. Diabetic medicine: a journal of the British Diabetic Association. 2011 Feb;28(2):199-205.

49. Persson U, Ödegaard K. Fetma ett ekonomiskt samhällsproblem – kostnader och möjliga åtgärder för Sverige. Ekonomisk Debatt. 2011;39(1):39-49.

50. Ragnarson Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia. 2001 Nov;44(11):2077-87.

51. Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot & ankle international. 1995 Jul;16(7):388-94.

Contact


For more information, please contact: diabetesmodelling@ihe.se